We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




EHR Model Flags High-Risk Periods in Patients with Metastatic Breast Cancer

By HospiMedica International staff writers
Posted on 16 Sep 2026

Determining when patients with metastatic breast cancer are nearing the end of life remains difficult, often leading to intensive interventions with limited benefit. More...

Prognostic uncertainty can delay goals-of-care discussions, supportive services, and planning for symptom management, while clinicians may also overestimate survival. To support earlier, patient-centered decisions, researchers have developed a data-driven tool that identifies periods of elevated mortality risk across hospital and outpatient settings.

The metastatic breast cancer–specific prognostic model was developed by a team led at UNC Lineberger Comprehensive Cancer Center and the University of North Carolina at Chapel Hill School of Medicine (Chapel Hill, NC, USA). It estimates the probability of death within 30 or 90 days. The regression-based approach uses routinely collected electronic health record data, including laboratory results, vital signs, breast cancer subtype, and medications. The goal is to help oncologists recognize high‑risk periods and initiate timely discussions about care needs and patient preferences.

New findings published in JCO Oncology Practice on September 4, 2026 describe the development and validation of the model using CancerLinQ Discovery, a national oncology database with real‑world data. Unlike tools that combine multiple cancer types and underrepresent breast cancer, this model is specific to metastatic breast cancer and can identify high‑risk periods even for patients who have lived a long time with the disease. The variables most associated with increased risk align with familiar clinical signals, including worsening liver function, increased heart rate, escalating needs for pain medication, and declining ability to perform self‑care.

Investigators indicate the tool could be implemented in routine practice to support better end‑of‑life care. It may encourage reassessment of treatment options, earlier involvement of palliative care specialists when appropriate, and closer alignment of care plans with patient values and goals. Future studies are planned to determine how best to integrate the model into clinical workflows and to evaluate its impact on decision‑making by oncologists, patients, and caregivers.

"In our prognostic model, the variables most closely correlated with increased risk align with signals clinicians already recognize, like worsening liver function, increased heart rate, rising needs for pain medication and declining ability to care for oneself at home. Any clinician could tell you those are signs that a patient is getting sicker, but sometimes we still miss them and don't do enough to prepare patients and families,” said Emily Ray, M.D., M.P.H., medical oncologist at UNC Lineberger Comprehensive Cancer Center and associate professor in the UNC School of Medicine's Division of Oncology.

"Our model reinforces that clinical intuition and could help oncologists better recognize these patterns and act on them to arrange more support for patients and caregivers," said Ray.

Related Links
UNC Lineberger Comprehensive Cancer Center 
UNC School of Medicine


Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Medical Imaging

view channel
Image: Visual Abstract (Andrea Farolfi et al., Journal of Nuclear Medicine, 2026. DOI: 10.2967/jnumed.126.272108)

PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI

Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.